Publications (33) Alfonso Jesús Domínguez-Gil Hurlé publications

filter_list Internal Medicine

2016

  1. A pharmacist's role in the individualization of treatment of HIV patients

    Personalized Medicine, Vol. 13, Núm. 2, pp. 169-188

  2. Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients

    Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355

  3. Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39

2015

  1. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman

    Clinical drug investigation, Vol. 35, Núm. 1, pp. 61-66

2014

  1. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2013

  1. Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study

    Patient Preference and Adherence, Vol. 7, pp. 729-739

2011

  1. Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  2. Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients

    Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582

2009

  1. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: An observational, open-label, multicentre study

    Drugs and Aging, Vol. 26, Núm. 7, pp. 617-626

  2. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2008

  1. Farmacogenética en oncología

    Medicina Clinica, Vol. 131, Núm. 5, pp. 184-195

2007

  1. Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery

    Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 5, pp. 1074-1079

2006

  1. Preventable adverse drug events in hospitalized patients

    Medicina Clinica, Vol. 126, Núm. 3, pp. 81-87

  2. Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions

    Clinical Microbiology and Infection, Vol. 12, Núm. SUPPL. 7, pp. 97-106

2005

  1. Antisense therapy in oncology: Present situation

    Farmacia Hospitalaria, Vol. 29, Núm. 4, pp. 269-282

  2. Zoledronic acid versus pamidronate: Cost minimisation in bone metastasis

    Journal of Medical Economics, Vol. 8, Núm. 1-12, pp. 1-12

2004

  1. Iniciación de un programa de monitorización de lamotrigina en pacientes epilépticos

    Atencion Farmaceutica, Vol. 6, Núm. 2, pp. 97-101

  2. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198

2002

  1. Amiodarone-induced skin pigmentation and pulmonary fibrosis

    Hospital Pharmacy, Vol. 37, Núm. 6, pp. 615-618

1999

  1. Population pharmacokinetics of amikacin in patients with haematological malignancies

    Journal of Antimicrobial Chemotherapy, Vol. 44, Núm. 2, pp. 235-242